Skip to content
Search

Latest Stories

Sri Lanka debt restructuring could take months: S&P

Sri Lanka debt restructuring could take months: S&P

S&P GLOBAL RATINGS said Wednesday (13) it could take months for Sri Lanka to restructure its foreign debt, a day after the country announced it would default on the $51 billion (£38.87 bn) it has borrowed.

It said it would likely assign Sri Lanka a "selective default" foreign currency rating after getting confirmation it misses the payment on interest coupons due on April 18.

S&P said it expected Sri Lanka would miss these payments and in the meantime, it lowered Sri Lanka's foreign currency sovereign rating to "CC", which means highly vulnerable to default.

Sri Lanka announced Tuesday (12) a default on its foreign debt as the island nation grapples with its worst economic crisis in memory and escalating protests demanding the government's resignation.

Acute food and fuel shortages, as well as long daily electricity blackouts, have brought widespread suffering to the country's 22 million people in its most painful downturn since independence in 1948.

The government has struggled to service foreign loans and Tuesday's decision comes ahead of negotiations for an International Monetary Fund bailout aimed at preventing a more catastrophic hard default that would see Sri Lanka completely repudiate its debts.

S&P said Sri Lanka was unlikely to be able to carry out a quick debt restructuring.

"Sri Lanka's debt restructuring process is likely to be complicated and may take months to complete," the ratings agency said.

"Negotiations with the IMF to establish a reform and funding programme are in the early stages," it added.

(AFP)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less